The Chemours Company stock steadies as PFAS litigation and Q2 loss weigh on outlook

Chemours stock held near $14.70 despite a $274 million Q2 loss and ongoing PFAS litigation risks, including a $455 million settlement with North Carolina, while revenue rose to $1.59 billion.